The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be
Study Name on ClinicalTrials.gov (link is external) |
A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis |
---|---|
Study Drug | GLPG2222 |
Type of Study Drug | CFTR modulator |
Study Title | A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis Harbouring One F508del CFTR Mutation and a Second Gating (Class III) Mutation |
Study Phase | 2a |
Study Sponsor | Galapagos |
Participating ECFS-CTN sites | Please contact ecfs-ctn@uzleuven.be for most recent sitelist |
Age | 18 Years to 99 Years |